Thyrocare Q2 results: Net profit up 31.75% to Rs 20.33 crore

The company reported a profit of Rs 15.43 crore in the same period last year.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Diagnostics player Thyrocare Technologies on October 31 reported a 31.75 percent year-on-year rise in consolidated net profit at Rs 20.33 crore for the July-September quarter of the current financial year, beating estimates.

The company reported a profit of Rs 15.43 crore in the same period last year.

Revenue came in at Rs 148 crore, up 9.65 percent from the year-ago quarter numbers of Rs 134.97 crore.

The company's reported earnings before interest, taxes, depreciation and amortization (EBITDA) were at Rs 36.70 crore, up from Rs 29.68 crore in the year-ago period. The EBITDA margin was at 27 percent against 24 percent in the year-ago period.

The company was awarded TB tenders under National Tuberculosis Elimi- nation Programme in Gujarat(13 Districts) for Drug Resistance testing of active TB patients and in Assam (3 Districts) for Latent TB detection in the quarter.

Thyrocare also entered into a Joint Venture agreement in Tanzania in the quarter. Thyrocare Laboratories (Tanzania) Limited was incorporated for this and operations setup is underway. The company plans an investment of USD 1 Million for lab setup and market development.

The company added that franchise revenue grew 20 percent Y-o-Y. Revenue from partnerships (excluding API & B2G) grew 22 percent Y-o-Y.

Revenue from diagnostic testing services grew 10.43 percent to Rs 136.75 crore in the quarter from Rs 123.83 crore. Diagnostic testing services contributed to 92 percent of the company's revenues.

The company added that finance cost increased because of interest expense on equipment finance availed for the new machines.

Shars of the company closed 2.09 percent up at Rs 549.30 on NSE.

(This is a developing story. Please check back for details)